E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Rhinosinusitis (CRS) |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic Rhinosinusitis (CRS) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to analyse whether Buparid/PARI
SINUS has a higher potential to avoid or postpone sinus surgery
in adult patients with CRS than Standard of Care therapy with
Budes® Nasal Spray. The results of this study are expected to
provide estimates for a proper sample size calculation to conduct
a pivotal study. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patient with confirmed diagnosis of chronic rhinosinusitis (CRS), i.e. inflammation of nasal mucosa and paranasal sinus. Diagnosis is based on history of symptoms (nasal obstruction, running nose, postnasal drip, facial pain and hyposmia with a duration of > 3 months) and on MRT-imaging
2. Patient without alternative other than sinus surgery
3. Patient’s written informed consent obtained prior to any screening or study-specific procedure
4. Male or female, equal/over 18 years of age
5. Patient is able to undergo nasal therapy without restrictions
6. Capable to correctly use the PARI SINUS device in accordance with the package insert
7. Capable of understanding the purpose and risk of the clinical trial
8. Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration. Both women and men must agree to use a medically acceptable method of contraception throughout the IMP treatment period and for 3 months after IMP discontinuation.
9. Patient is able to participate in the study according to Investigator’s opinion |
|
E.4 | Principal exclusion criteria |
1. Patients with cystic fibrosis
2. Patients with polyposis nasi grade I-IV
3. Patients with prior FESS (Functional Endosopic Sinus Surgery)
4. Pregnant or breastfeeding women
5. Any active invasive bacterial, viral or fungal infection within
one week prior to first investigational medicinal product administration
6. No clinically relevant abnormal parameters of vital signs, blood biochemistry or renal/hepatic function
7. Unlikely to comply with visits, inhalation procedures or other measurements scheduled in the protocol
8. Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP
9. Any co-existing medical condition that in the Investigator’s judgement will substantially increase the risk associated with the patient’s participation in the clinical trial
10. Psychiatric disorders or altered mental status precluding
understanding of the informed consent process and/or completion of the necessary procedures
11. Drug or alcohol abuse
12. End-stage malignancies
13. Known hypersensitivity to Budesonide
14. Patients with oral steroid therapy within the last 3 months
15. Patients needing > 1 mg/day Budesonide (or steroidal equivalent) for therapy of asthma
16. Patients on therapy with leukotriene receptor
antagonists, decongestants, antihistamines or antibiotics
17. Patients with frequent epistaxis (> 1 episode per week) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy:
Health-related quality of life
Nasal obstruction
Inflammation of nasal mucosa and paranasal sinus
Clinical parameters
Symptoms of rhinosinusitis
Loss of taste/Loss of smell
Avoidance or postponing of sinus surgery
Customer satisfaction regarding the PARI SINUS device, if applicable
Safety:
Treatment-emergent adverse events (AEs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Efficacy:
Health-related quality of life at Visit 0, 1, 2, 3, 4, 5 and 6
Nasal obstruction at Visit 0, 1, 2 and 3
Inflammation of the nasal mucosa and paranasal sinus at Visit 1 and Visit 3
Clinical parameters at Visit 0, 3 and 6
Symptoms of rhinosinusitis at Visit 0, 1, 2, 3, 4, 5 and 6
Loss of taste/Loss of smell at Visit 0, 1, 3 and 6
Avoidance or postponing of sinus surgery at Visit 3, 4, 5 and 6
Safety: During the whole study period |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |